Subscribe to Updates
Get the latest creative news from FooBar about art, design and business.
Browsing: FDA
The FDA launched the Global Reliance Disclosure Program to share approval data with foreign regulators, aiming to speed patient access to medicines worldwide.
The FDA approved Sunharbo (asundexian) to help prevent recurrent stroke in adults at high risk, offering a new treatment option alongside existing antiplatelet therapies.
The FDA has approved Rybrevant Faspro for adults with recurrent or metastatic head and neck squamous cell carcinoma who have progressed on prior therapies.
The FDA released final guidance requiring manufacturers to implement a potency assurance strategy for cell and gene therapy products to ensure they perform as intended.
The FDA has approved Fayuvi, a gene therapy for Sanfilippo syndrome, a rare inherited disease. The treatment costs nearly $4 million per patient.
The FDA granted accelerated approval for Voceryq, the first plasmid DNA-based immunotherapy for adults with recurrent respiratory papillomatosis, a rare condition caused by HPV.
Most FDA scientists opposed the Trump administration’s move to ease access to unproven peptide drugs favored by Health Secretary Robert F Kennedy Jr.
The Department of Health and Human Services will allow small pharmacies to compound six popular peptides, moving them from the gray market to regulated facilities.
The FDA launched the Neuroscience Advancement and Innovation Nexus to accelerate medical product development for brain conditions, starting with Alzheimer’s prevention.
The FDA approved Hibsago, the first antisense oligonucleotide for chronic hepatitis b treatment, allowing some patients to stop therapy while maintaining viral control.
